Market Cap 3.45B
Revenue (ttm) 182.95M
Net Income (ttm) -115.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -63.16%
Debt to Equity Ratio 0.22
Volume 452,600
Avg Vol 514,008
Day's Range N/A - N/A
Shares Out 42.45M
Stochastic %K 45%
Beta 0.74
Analysts Strong Sell
Price Target $86.78

Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 409 1801
Address:
15440 Laguna Canyon Road, Suite 160, Irvine, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:45 AM
$TARS: The current market context shows a strong upward momentum as indicated by the RSI of 62.5, suggesting the stock is approaching overbought territory but still has room to run. The last close at $81.71 is above the 30-day moving average (MA30) of $76.28 and the 50-day moving average (MA50) of $73.4, reinforcing a bullish bias. The price is also closer to the 60-day high of $85.25, indicating potential resistance ahead. Actionable Trade Plan: - Suggested Entry: $82.00 - Stop Loss: $78.00 (4.88% risk) - Take Profit Targets: 1. $84.00 (2.44% gain) 2. $86.00 (4.88% gain) 3. $95.00 (15.92% gain) With the third target offering a potential ROI of 17% or more, this trade aligns with the current bullish sentiment. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 1:33 AM
$TARS Current Stock Price: $81.34 Contracts to trade: $80 TARS Dec 19 2025 Call Entry: $0.50 Exit: $0.98 ROI: 96% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:48 AM
$TARS: Current market context shows a strong bullish sentiment with the last close at $79.55. The RSI at 57.58 indicates that the stock is neither overbought nor oversold, suggesting room for upward movement. The price is above the 30-day MA of $75.35 and the 50-day MA of $72.48, reinforcing a bullish directional bias. The stock is currently trading closer to the 60-day high of $85.25, indicating potential for further gains. Action Plan: - Suggested Entry: $79.55 - Stop Loss: $76.10 (approximately 4.3% below entry) - Take Profit Targets: - TP1: $83.00 (4.8% gain) - TP2: $86.00 (8.0% gain) - TP3: $93.00 (16.9% gain) This plan provides a solid risk-reward ratio, with TP3 offering an ROI of 17% or more. Monitor the stock closely for any volatility, as indicated by the ATR of 3.45. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 4:18 PM
Barclays updates rating for Tarsus Pharmaceuticals ( $TARS ) to Overweight, target set at 100.
0 · Reply
Hawksssss
Hawksssss Dec. 9 at 2:35 PM
$TARS new all time high
1 · Reply
Biotechace
Biotechace Dec. 9 at 1:13 PM
$TARS Barclay's initiates coverage on TARS with $100 12 month price target!
0 · Reply
Biotechace
Biotechace Dec. 9 at 12:49 PM
$TARS JUMP Financial purchases 188,317 TARS shares
0 · Reply
Biotechace
Biotechace Dec. 9 at 12:48 PM
$TARS Norges Bank acquires 471,354 TARS shares
0 · Reply
Biotechace
Biotechace Dec. 9 at 12:34 PM
$TARS Gurufocus GF Value $158.84 today
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:36 AM
$TARS Trade Alert: Market Context: $TARS is currently trading at $83.13, showing strong momentum with an RSI of 74.83, indicating overbought conditions. The stock is above its 30-day MA of 75.0 and 50-day MA of 72.06, suggesting a bullish trend. However, the high of $83.77 within the last 60 days indicates potential resistance. Directional Bias: The RSI above 70 signals caution, but the stock remains in an uptrend. The price is near its 60D high, suggesting a potential pullback. Trade Plan: - Suggested Entry: $83.00 - Stop Loss: $80.00 (3.6% risk) - Take Profit Targets: 1. TP1: $86.00 (3.5% gain) 2. TP2: $89.00 (7.1% gain) 3. TP3: $97.00 (16.7% gain) With a well-structured trade plan, the potential ROI on TP3 exceeds 17%. Monitor closely for price action around the resistance level. https://privateprofiteers.com
0 · Reply
Latest News on TARS
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3

Nov 20, 2025, 1:46 PM EST - 23 days ago

Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3


Tarsus to Participate in Upcoming Investor Conferences

Aug 27, 2025, 5:00 PM EDT - 3 months ago

Tarsus to Participate in Upcoming Investor Conferences


Top 2 Health Care Stocks That May Fall Off A Cliff In August

Aug 20, 2025, 8:46 AM EDT - 4 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff In August

PINC


Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off

May 12, 2025, 12:28 PM EDT - 7 months ago

Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off


Tarsus Announces Proposed $100.0 Million Public Offering

Mar 12, 2025, 4:12 PM EDT - 9 months ago

Tarsus Announces Proposed $100.0 Million Public Offering


Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Mar 11, 2025, 12:36 PM EDT - 9 months ago

Tarsus Pharma: Strong Execution In Xdemvy Commercialization


Tarsus to Participate in Upcoming Investor Conference

Mar 6, 2025, 5:00 PM EST - 10 months ago

Tarsus to Participate in Upcoming Investor Conference


Tarsus to Participate at Upcoming Investor Conferences

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tarsus to Participate at Upcoming Investor Conferences


Tarsus Announces Pricing of $100.0 Million Public Offering

Mar 1, 2024, 12:07 AM EST - 1 year ago

Tarsus Announces Pricing of $100.0 Million Public Offering


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:45 AM
$TARS: The current market context shows a strong upward momentum as indicated by the RSI of 62.5, suggesting the stock is approaching overbought territory but still has room to run. The last close at $81.71 is above the 30-day moving average (MA30) of $76.28 and the 50-day moving average (MA50) of $73.4, reinforcing a bullish bias. The price is also closer to the 60-day high of $85.25, indicating potential resistance ahead. Actionable Trade Plan: - Suggested Entry: $82.00 - Stop Loss: $78.00 (4.88% risk) - Take Profit Targets: 1. $84.00 (2.44% gain) 2. $86.00 (4.88% gain) 3. $95.00 (15.92% gain) With the third target offering a potential ROI of 17% or more, this trade aligns with the current bullish sentiment. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 1:33 AM
$TARS Current Stock Price: $81.34 Contracts to trade: $80 TARS Dec 19 2025 Call Entry: $0.50 Exit: $0.98 ROI: 96% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:48 AM
$TARS: Current market context shows a strong bullish sentiment with the last close at $79.55. The RSI at 57.58 indicates that the stock is neither overbought nor oversold, suggesting room for upward movement. The price is above the 30-day MA of $75.35 and the 50-day MA of $72.48, reinforcing a bullish directional bias. The stock is currently trading closer to the 60-day high of $85.25, indicating potential for further gains. Action Plan: - Suggested Entry: $79.55 - Stop Loss: $76.10 (approximately 4.3% below entry) - Take Profit Targets: - TP1: $83.00 (4.8% gain) - TP2: $86.00 (8.0% gain) - TP3: $93.00 (16.9% gain) This plan provides a solid risk-reward ratio, with TP3 offering an ROI of 17% or more. Monitor the stock closely for any volatility, as indicated by the ATR of 3.45. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 4:18 PM
Barclays updates rating for Tarsus Pharmaceuticals ( $TARS ) to Overweight, target set at 100.
0 · Reply
Hawksssss
Hawksssss Dec. 9 at 2:35 PM
$TARS new all time high
1 · Reply
Biotechace
Biotechace Dec. 9 at 1:13 PM
$TARS Barclay's initiates coverage on TARS with $100 12 month price target!
0 · Reply
Biotechace
Biotechace Dec. 9 at 12:49 PM
$TARS JUMP Financial purchases 188,317 TARS shares
0 · Reply
Biotechace
Biotechace Dec. 9 at 12:48 PM
$TARS Norges Bank acquires 471,354 TARS shares
0 · Reply
Biotechace
Biotechace Dec. 9 at 12:34 PM
$TARS Gurufocus GF Value $158.84 today
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:36 AM
$TARS Trade Alert: Market Context: $TARS is currently trading at $83.13, showing strong momentum with an RSI of 74.83, indicating overbought conditions. The stock is above its 30-day MA of 75.0 and 50-day MA of 72.06, suggesting a bullish trend. However, the high of $83.77 within the last 60 days indicates potential resistance. Directional Bias: The RSI above 70 signals caution, but the stock remains in an uptrend. The price is near its 60D high, suggesting a potential pullback. Trade Plan: - Suggested Entry: $83.00 - Stop Loss: $80.00 (3.6% risk) - Take Profit Targets: 1. TP1: $86.00 (3.5% gain) 2. TP2: $89.00 (7.1% gain) 3. TP3: $97.00 (16.7% gain) With a well-structured trade plan, the potential ROI on TP3 exceeds 17%. Monitor closely for price action around the resistance level. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:35 AM
$TARS: The stock closed at $81.83, showing strong momentum with an RSI of 75.47, indicating it is in overbought territory. However, the price is above the 30-day MA of $73.98 and the 50-day MA of $71.00, suggesting bullish sentiment in the near term. The recent 60-day high of $83.47 provides a key resistance level, while the low of $48.2 indicates significant volatility. Actionable Trade Alert: - Suggested Entry: $81.83 - Stop Loss: $78.21 (approximately 4% below entry) - Take Profit Targets: 1. $83.47 (60D High) - 2% ROI 2. $85.00 - 3% ROI 3. $95.00 - 16.1% ROI Given the current RSI and moving averages, the directional bias is bullish, but caution is advised due to overbought conditions. Monitor for potential pullbacks. This plan aims for a minimum of 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:10 PM
$TARS: The stock closed at $81.83, showing strong momentum with an RSI of 75.47, indicating it is in overbought territory. However, the price is above the 30-day MA of $73.98 and the 50-day MA of $71.00, suggesting bullish sentiment in the near term. The recent 60-day high of $83.47 provides a key resistance level, while the low of $48.2 indicates significant volatility. Actionable Trade Alert: - Suggested Entry: $81.83 - Stop Loss: $78.21 (approximately 4% below entry) - Take Profit Targets: 1. $83.47 (60D High) - 2% ROI 2. $85.00 - 3% ROI 3. $95.00 - 16.1% ROI Given the current RSI and moving averages, the directional bias is bullish, but caution is advised due to overbought conditions. Monitor for potential pullbacks. This plan aims for a minimum of 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
BostonNorth
BostonNorth Dec. 4 at 1:01 PM
$ADMA $AXSM $MIRM $SPRY $TARS Let’s goooooooooo
0 · Reply
BostonNorth
BostonNorth Dec. 4 at 12:52 PM
1 · Reply
Hawksssss
Hawksssss Dec. 4 at 4:03 AM
$TARS new all time high
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 4 at 3:14 AM
Attached is a schedule of revenue multiples of all new/recent comm'l-stage oncology & non-oncology with 1st approvals since 1/1/20 & current market caps between $750MM & $5B ($1B - $5B in non-oncology). Note the peer group averages at the bottom in bold. Oncology continues to trade at meaningfully lower multiples than non. However, one can see via a casual review the oncology peer group had more recent approvals. $AUPH was a head scratcher trading at a high multiple where Lupkynis was approved 1/22/2021. AUPH traded meaningfully lower today when the XBI was otherwise strong. Is AUPH trading down to a market (v premium) multiple? $TARS & $ARQT have more or less the same FY2029 revenue estimate as $SNDX yet SNDX trades at a much lower market cap. $IOVA needs to demonstrate it can scale gross margin but the recent lung cancer data is compelling. Patients with these awful lung cancers will use IOVA's TIL. The brutal, rotten unfortunate truth is there are no better options. In time...
1 · Reply
BostonNorth
BostonNorth Dec. 3 at 11:08 PM
0 · Reply
Creyedr
Creyedr Dec. 2 at 3:26 PM
$TARS still love this stock and Xdemvy is continuing to impress and shatter script expectations.
0 · Reply
Hawksssss
Hawksssss Nov. 26 at 10:42 PM
$TARS nice. Closing above 80
1 · Reply
Biotechace
Biotechace Nov. 25 at 1:20 PM
$TARS can we make it to $85 today? Let's go! Triple digits by Dec 31? Let's go!
0 · Reply
BostonNorth
BostonNorth Nov. 25 at 2:36 AM
$ADMA $AXSM $MIRM $SPRY $TARS Not bad action…only three trading sessions and a big jump since this post. Granted it was bleeding for a long time.
0 · Reply
Hawksssss
Hawksssss Nov. 24 at 10:04 PM
$TARS all time high
0 · Reply